SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

The past, present and future of hypertension management: a potential role for AT1-receptor antagonists

Norman K Hollenberg

Department of Radiology and Medicine, Brigham and Women's Hospital Boston, Massachusetts, USA

Peter S Sever

Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Hospital, London, UK

The benefits of effective antihypertensive treatment were established at least 40 years ago, but despite the availability of more reliable and better-tolerated antihypertensive drugs, the control of blood pressure remains poor in most patients. Long-term antihypertensive efficacy requires treatment that combines reliable 24-hour reduction of blood pressure with good tolerability to facilitate patient compliance.Treatment should also protect against target-organ damage.As the majority of negative cardiovascular effects of angiotensin II are mediated through the angiotensin II type 1 (AT1) receptor, specific blockade of this receptor is a rational approach for achieving these ideals. Several AT1-receptor blockers have been developed that combine antihypertensive efficacy and placebo-like tolerability — the latter being unique in the history of antihypertensive therapy. In experimental animals these drugs prevent or reverse target organ damage in the heart, the vasculature and the kidney. Ongoing large-scale outcome studies are now underway to establish the benefits of AT1-receptor blockade beyond blood pressure control.

Key Words: hypertension • renin-angiotensin-aldosterone system • angiotensin receptor antagonists

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1, 5-10 (2000)
DOI: 10.3317/jraas.2000.011
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement